Creating new treatments for triple negative breast cancer using adenosine receptor blockers
Developing purinergic receptor inverse agonists for treating triple negative breast cancer
['FUNDING_R01'] · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · NIH-11133920
This study is looking at new medications that could help treat advanced triple negative breast cancer, which is a tough type of cancer that mainly affects younger women and doesn't respond well to standard treatments, with the hope of making treatment more effective and easier to tolerate.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TEXAS HLTH SCIENCE CENTER (nih funded) |
| Locations | 1 site (SAN ANTONIO, UNITED STATES) |
| Trial ID | NIH-11133920 on ClinicalTrials.gov |
What this research studies
This research focuses on developing innovative drugs that block adenosine receptors to treat metastatic triple negative breast cancer (TNBC), a particularly aggressive form of breast cancer. TNBC often affects younger women and has limited treatment options due to its negative hormone receptor status. The study aims to overcome the challenges of conventional chemotherapy, which often leads to drug resistance and has poor tolerability. By targeting specific receptors involved in cancer growth and immune suppression, the research seeks to improve treatment outcomes for patients with late-stage TNBC.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with metastatic triple negative breast cancer, particularly younger women and those from underrepresented communities.
Not a fit: Patients with other types of breast cancer or those whose cancer is not metastatic may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, more effective treatment option for patients suffering from triple negative breast cancer.
How similar studies have performed: Previous research has shown promise in targeting adenosine receptors for cancer treatment, indicating that this approach could be a viable option for improving outcomes in TNBC.
Where this research is happening
SAN ANTONIO, UNITED STATES
- UNIVERSITY OF TEXAS HLTH SCIENCE CENTER — SAN ANTONIO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: JIANG, JEAN X — UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
- Study coordinator: JIANG, JEAN X
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.